A district court judge vanquished Janssen Biotech Inc.'s hopes of delaying the launch of Celltrion Inc./Pfizer Inc.'s Remicade (infliximab) biosimilar until the composition patent expires in September 2018.
Massachusetts District Court Judge Mark Wolf issued an oral ruling Aug. 17 that the patent, No. 6,284,471, which covers the...





